S&P Global Inc vs Stryker Corporation — how do they compare? S&P Global Inc trades at $406.16 (market cap $118.72B), while Stryker Corporation trades at $278.77 (market cap $106.24B). The key difference: S&P Global Inc and Stryker Corporation are close in size by market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Stryker Corporation for 20 Days on average.
| SPGI | SYK | |
|---|---|---|
Market Cap | $118.72B | $106.24B |
Volume | 1,647,917 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $517.92 | $388.35 |
52-Week Low | $370.42 | $269.75 |
Typical Hold Time | 123 Days | 20 Days |
Enterprise Value | $130.21B | $117.70B |
Dividend Yield | 0.96% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust financials with $15.34B revenue and 30.54% net income margin for 2025, while recent earnings show mixed quarterly performance. Analyst consensus remains strongly bullish with an $509.50 price target, supported by 24 buy ratings. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The stock presents a compelling long-term investment opportunity given its strong profitability, market leadership, and analyst support, though technical indicators suggest near-term caution. Key risks include market volatility and execution of growth initiatives, while the 29% upside to consensus target offers significant potential reward for patient investors.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →